| HUSA, Petr, Marian OLTMAN, Ljubomire IVANOVSKI, Vratislav ŘEHÁK, Diethelm MESSINGER, Andreas TIETZ a Petr URBÁNEK. Efficacy and safety of peginterferon alpha-2a (40 kD) plus ribavirin among patients with chronic hepatitis C and earlier treatment failure to interferon and ribavirin: an open-label study in central and Eastern Europe. Online. European Journal of Gastroenterology & Hepatology. London UK: Lippincott, Williams and Wilkins, 2011, roč. 23, č. 5, s. 375-381. ISSN 0954-691X. Dostupné z: https://dx.doi.org/10.1097/MEG.0b013e3283458407. [citováno 2024-04-23] |
Další formáty:
BibTeX
LaTeX
RIS
@article{935740,
author = {Husa, Petr and Oltman, Marian and Ivanovski, Ljubomire and Řehák, Vratislav and Messinger, Diethelm and Tietz, Andreas and Urbánek, Petr},
article_location = {London UK},
article_number = {5},
doi = {http://dx.doi.org/10.1097/MEG.0b013e3283458407},
keywords = {HCV; Hepatitis C; peginterferon alfa-2a; cure},
language = {eng},
issn = {0954-691X},
journal = {European Journal of Gastroenterology & Hepatology},
title = {Efficacy and safety of peginterferon alpha-2a (40 kD) plus ribavirin among patients with chronic hepatitis C and earlier treatment failure to interferon and ribavirin: an open-label study in central and Eastern Europe},
volume = {23},
year = {2011}
}
TY - JOUR
ID - 935740
AU - Husa, Petr - Oltman, Marian - Ivanovski, Ljubomire - Řehák, Vratislav - Messinger, Diethelm - Tietz, Andreas - Urbánek, Petr
PY - 2011
TI - Efficacy and safety of peginterferon alpha-2a (40 kD) plus ribavirin among patients with chronic hepatitis C and earlier treatment failure to interferon and ribavirin: an open-label study in central and Eastern Europe
JF - European Journal of Gastroenterology & Hepatology
VL - 23
IS - 5
SP - 375-381
EP - 375-381
PB - Lippincott, Williams and Wilkins
SN - 0954691X
KW - HCV
KW - Hepatitis C
KW - peginterferon alfa-2a
KW - cure
N2 - Methods: HCV genotype 1 patients previously treated with conventional interferon with or without ribavirin were assigned to 48 weeks of treatment with peginterferon alfa-2a (40KD) 180 mcg/week plus ribavirin (recommended dose 1000/1200 mg/day) in this open-label trial conducted in Central and Eastern Europe. The primary efficacy endpoint was sustained virological response (SVR, HCV RNA <50 IU/mL) after 24 weeks of untreated follow-up. Early virological response (EVR) was defined as undetectable HCV RNA or minimally 2-log drop at week 12. Results: 154/203 (76%) treatment-experienced genotype 1 patients completed treatment. Overall, 113 patients (56%) achieved an EVR, 107 (53%) had an end-of-treatment response and 63 patients (31%) achieved an SVR (including 38% [40/105] of those with prior breakthrough or relapse and 24% [21/88] of those with prior non-response). Among patients with an EVR 47% (53/113) achieved an SVR (positive predictive value = 47%), compared with 3% (1/34) of patients without EVR.
ER -
HUSA, Petr, Marian OLTMAN, Ljubomire IVANOVSKI, Vratislav ŘEHÁK, Diethelm MESSINGER, Andreas TIETZ a Petr URBÁNEK. Efficacy and safety of peginterferon alpha-2a (40 kD) plus ribavirin among patients with chronic hepatitis C and earlier treatment failure to interferon and ribavirin: an open-label study in central and Eastern Europe. Online. \textit{European Journal of Gastroenterology \&{} Hepatology}. London UK: Lippincott, Williams and Wilkins, 2011, roč.~23, č.~5, s.~375-381. ISSN~0954-691X. Dostupné z: https://dx.doi.org/10.1097/MEG.0b013e3283458407. [citováno 2024-04-23]
|
